View ValuationCareRx 将来の成長Future 基準チェック /06CareRxの収益は年間54.6%で減少すると予測されていますが、年間収益は年間4%で増加すると予想されています。EPS は年間12.5%で減少すると予想されています。主要情報-54.6%収益成長率-12.51%EPS成長率Consumer Retailing 収益成長9.2%収益成長率4.0%将来の株主資本利益率n/aアナリストカバレッジGood最終更新日11 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 11CareRx Corporation announces Quarterly dividend, payable on July 09, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on July 09, 2026, ex-date on June 23, 2026 and record date on June 23, 2026.お知らせ • Apr 28CareRx Corporation to Report Q1, 2026 Results on May 06, 2026CareRx Corporation announced that they will report Q1, 2026 results After-Market on May 06, 2026お知らせ • Mar 17CareRx Corporation, Annual General Meeting, May 28, 2026CareRx Corporation, Annual General Meeting, May 28, 2026.お知らせ • Mar 10CareRx Corporation announces Quarterly dividend, payable on April 09, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on April 09, 2026, ex-date on March 19, 2026 and record date on March 19, 2026.お知らせ • Feb 25CareRx Corporation to Report Q4, 2025 Results on Mar 04, 2026CareRx Corporation announced that they will report Q4, 2025 results After-Market on Mar 04, 2026お知らせ • Dec 17CareRx Corporation announces Quarterly dividend, payable on January 21, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on January 21, 2026, ex-date on December 23, 2025 and record date on December 23, 2025.お知らせ • Oct 24CareRx Corporation to Report Q3, 2025 Results on Nov 03, 2025CareRx Corporation announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2025お知らせ • Sep 17CareRx Corporation announces Quarterly dividend, payable on October 15, 2025CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on October 15, 2025, ex-date on September 23, 2025 and record date on September 23, 2025.お知らせ • Jul 21CareRx Corporation to Report Q2, 2025 Results on Jul 30, 2025CareRx Corporation announced that they will report Q2, 2025 results After-Market on Jul 30, 2025お知らせ • May 01CareRx Corporation to Report Q1, 2025 Results on May 07, 2025CareRx Corporation announced that they will report Q1, 2025 results at 7:00 AM, US Eastern Standard Time on May 07, 2025お知らせ • Mar 25CareRx Corporation, Annual General Meeting, Jun 05, 2025CareRx Corporation, Annual General Meeting, Jun 05, 2025.お知らせ • Feb 26CareRx Corporation to Report Q4, 2024 Results on Mar 05, 2025CareRx Corporation announced that they will report Q4, 2024 results at 7:00 AM, US Eastern Standard Time on Mar 05, 2025お知らせ • Oct 31CareRx Corporation to Report Q3, 2024 Results on Nov 08, 2024CareRx Corporation announced that they will report Q3, 2024 results at 7:00 AM, Eastern Standard Time on Nov 08, 2024お知らせ • Sep 05CareRx Corporation Appoints Suzanne Brand as Chief Financial Officer, Effective October 1, 2024CareRx Corporation announced that following an extensive executive search process, Suzanne Brand will be joining the Company in the role of Chief Financial Officer effective October 1, 2024. Ms. Brand is a highly accomplished executive, bringing a wealth of financial, healthcare and leadership experience. She joins CareRx from Teva Pharmaceuticals, a leading global manufacturer of quality generic and innovative pharmaceuticals, where she has held several senior finance roles since 2011, most recently serving as CFO of Teva Canada. Prior to joining Teva, Ms. Brand spent twelve years in finance at Wyeth Pharmaceuticals, a Pfizer company, where she held senior roles including as a Director, Commercial and Corporate Finance. She began her career as an auditor at PriceWaterhouseCoopers (PwC). Ms. Brand is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Science degree in Biology and Business from the University of Toronto.お知らせ • Aug 02CareRx Corporation to Report Q2, 2024 Results on Aug 08, 2024CareRx Corporation announced that they will report Q2, 2024 results at 7:00 AM, US Eastern Standard Time on Aug 08, 2024お知らせ • May 30CareRx Corporation Announces Board ChangesCareRx Corporation announced that as part of the Company's commitment to Board refreshment and to realign Board functions to match the Company's strategic focus on operational performance, Kevin Dalton, Chairman of the Board for the last six years, will be retiring as Chairman effectively immediately. Mr. Dalton will be succeeded by Jeff Watson, a current independent director of the Board. Mr. Dalton will be stepping into the role as Chair of the Compensation, Nominating and Governance Committee in place of Maria Perrella, who will continue to remain Chair of the Audit Committee. Mr. Watson has served on the Board of CareRx since 2023 and brings over three decades of experience in the healthcare industry, having most recently served as the President and CEO of Apotex from 2018 to 2023. Mr. Watson currently represents SK Capital Partners on two of their portfolio company boards for Apotex and Woodstock Sterile Solutions, and has previously served on numerous other boards, including as a board member and Chair of the Association for Accessible Medicines (AAM), Chair of the Canadian Generic Pharmaceutical Association (CGPA), and former Chair of the US Healthcare Distribution Alliance's (HDA) knowledge partner, the HDA Research Foundation.お知らせ • May 15CareRx Corporation Announces CFO TransitionCareRx Corporation announced that Andrew Mok will step down as Chief Financial Officer effective June 7, 2024, to pursue another employment opportunity. The Company is undertaking a search for a new CFO. Davide Pernarella, currently Vice President, Business Planning and Analysis at CareRx, will assume the role of Interim Chief Financial Officer following Mr. Mok's departure. Mr. Pernarella has worked at CareRx for over seven years in various roles with increasing responsibility, and has an intimate knowledge of the financial and business affairs of the Company. Prior to joining CareRx, he held roles in the Transaction Services and Assurance groups at KPMG Canada. Mr. Pernarella is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Commerce degree from the Rotman School of Management at the University of Toronto.お知らせ • Mar 15CareRx Corporation, Annual General Meeting, May 28, 2024CareRx Corporation, Annual General Meeting, May 28, 2024.お知らせ • Mar 08CareRx Corporation Reports Goodwill and Intangible Assets Impairment Charges for the Fourth Quarter Ended December 31, 2023CareRx Corporation reported goodwill and intangible assets impairment of $710,000 for the fourth quarter ended December 31, 2023.お知らせ • Mar 01CareRx Corporation to Report Q4, 2023 Results on Mar 07, 2024CareRx Corporation announced that they will report Q4, 2023 results at 7:00 AM, US Eastern Standard Time on Mar 07, 2024お知らせ • Nov 02CareRx Corporation to Report Q3, 2023 Results on Nov 08, 2023CareRx Corporation announced that they will report Q3, 2023 results at 7:00 AM, US Eastern Standard Time on Nov 08, 2023お知らせ • Aug 04CareRx Corporation to Report Q2, 2023 Results on Aug 10, 2023CareRx Corporation announced that they will report Q2, 2023 results at 7:00 AM, US Eastern Standard Time on Aug 10, 2023お知らせ • Jun 07Carerx Corporation Announces Director ChangesCareRx Corporation appointed Puneet Khanna and Jeff Watson as directors. Company announced that Matt Hills did not stand for re-election.お知らせ • Jan 19CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million.CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,963,000 Price\Range: CAD 2.7 Discount Per Security: CAD 0.162お知らせ • May 21CareRx Corporation announced that it has received CAD 63.250644 million in funding from Yorkville Asset Management Inc.On May 19, 2021, CareRx Corporation (TSX:CRRX) closed the transaction. The company issued a total of 12,524,880 subscription receipts for gross proceeds of CAD 63,250,644. The transaction included a portion of non-brokered placement from returning investor Yorkville Asset Management Inc. for 2,277,230 subscription receipts for proceeds of CAD 11,500,011.5 and brokered portion of 10,247,650 subscription receipts for proceeds of CAD 51,750,632.5.業績と収益の成長予測OTCPK:CHHH.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028415830N/A312/31/2027406826N/A612/31/20263856163373/31/2026375272230N/A12/31/2025370262331N/A9/30/202536602130N/A6/30/2025366-22332N/A3/31/2025367-42836N/A12/31/2024367-53038N/A9/30/2024366-63138N/A6/30/2024367-72734N/A3/31/2024369-42332N/A12/31/2023371-51927N/A9/30/2023374-62533N/A6/30/2023378-73038N/A3/31/2023380-341629N/A12/31/2022382-34922N/A9/30/2022384-34-411N/A6/30/2022358-36-510N/A3/31/2022311-20-18N/A12/31/2021263-2307N/A9/30/2021212-2127N/A6/30/2021187-24-6-3N/A3/31/2021177-29-20N/A12/31/2020162-18-20N/A9/30/2020148-50-3-1N/A6/30/2020134-47-20N/A3/31/2020126-34-12N/A12/31/2019125-46N/A6N/A9/30/2019122-19N/A3N/A6/30/2019119-20N/A4N/A3/31/2019117-39N/A9N/A12/31/2018119-35N/A7N/A9/30/201885-27N/A14N/A6/30/201897-23N/A12N/A3/31/2018110-3N/A15N/A12/31/2017122-4N/A16N/A9/30/2017168-6N/A14N/A6/30/2017170-3N/A24N/A3/31/2017170-13N/A10N/A12/31/2016167-18N/A2N/A9/30/2016166-21N/A6N/A6/30/2016166-34N/A3N/A3/31/2016164-30N/A20N/A12/31/2015161-35N/A29N/A9/30/201527-47N/A28N/A6/30/201560-48N/A22N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CHHH.Fの収益は今後 3 年間で減少すると予測されています (年間-54.6% )。収益対市場: CHHH.Fの収益は今後 3 年間で減少すると予測されています (年間-54.6% )。高成長収益: CHHH.Fの収益は今後 3 年間で減少すると予測されています。収益対市場: CHHH.Fの収益 ( 4% ) US市場 ( 11.7% ) よりも低い成長が予測されています。高い収益成長: CHHH.Fの収益 ( 4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CHHH.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YConsumer-retailing 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 04:04終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CareRx Corporation 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Kyle McPheeATB CormarkKyle McPheeATB Cormark Historical (Cormark Securities)Doug CooperBeacon Securities Limited8 その他のアナリストを表示
お知らせ • May 11CareRx Corporation announces Quarterly dividend, payable on July 09, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on July 09, 2026, ex-date on June 23, 2026 and record date on June 23, 2026.
お知らせ • Apr 28CareRx Corporation to Report Q1, 2026 Results on May 06, 2026CareRx Corporation announced that they will report Q1, 2026 results After-Market on May 06, 2026
お知らせ • Mar 17CareRx Corporation, Annual General Meeting, May 28, 2026CareRx Corporation, Annual General Meeting, May 28, 2026.
お知らせ • Mar 10CareRx Corporation announces Quarterly dividend, payable on April 09, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on April 09, 2026, ex-date on March 19, 2026 and record date on March 19, 2026.
お知らせ • Feb 25CareRx Corporation to Report Q4, 2025 Results on Mar 04, 2026CareRx Corporation announced that they will report Q4, 2025 results After-Market on Mar 04, 2026
お知らせ • Dec 17CareRx Corporation announces Quarterly dividend, payable on January 21, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on January 21, 2026, ex-date on December 23, 2025 and record date on December 23, 2025.
お知らせ • Oct 24CareRx Corporation to Report Q3, 2025 Results on Nov 03, 2025CareRx Corporation announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2025
お知らせ • Sep 17CareRx Corporation announces Quarterly dividend, payable on October 15, 2025CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on October 15, 2025, ex-date on September 23, 2025 and record date on September 23, 2025.
お知らせ • Jul 21CareRx Corporation to Report Q2, 2025 Results on Jul 30, 2025CareRx Corporation announced that they will report Q2, 2025 results After-Market on Jul 30, 2025
お知らせ • May 01CareRx Corporation to Report Q1, 2025 Results on May 07, 2025CareRx Corporation announced that they will report Q1, 2025 results at 7:00 AM, US Eastern Standard Time on May 07, 2025
お知らせ • Mar 25CareRx Corporation, Annual General Meeting, Jun 05, 2025CareRx Corporation, Annual General Meeting, Jun 05, 2025.
お知らせ • Feb 26CareRx Corporation to Report Q4, 2024 Results on Mar 05, 2025CareRx Corporation announced that they will report Q4, 2024 results at 7:00 AM, US Eastern Standard Time on Mar 05, 2025
お知らせ • Oct 31CareRx Corporation to Report Q3, 2024 Results on Nov 08, 2024CareRx Corporation announced that they will report Q3, 2024 results at 7:00 AM, Eastern Standard Time on Nov 08, 2024
お知らせ • Sep 05CareRx Corporation Appoints Suzanne Brand as Chief Financial Officer, Effective October 1, 2024CareRx Corporation announced that following an extensive executive search process, Suzanne Brand will be joining the Company in the role of Chief Financial Officer effective October 1, 2024. Ms. Brand is a highly accomplished executive, bringing a wealth of financial, healthcare and leadership experience. She joins CareRx from Teva Pharmaceuticals, a leading global manufacturer of quality generic and innovative pharmaceuticals, where she has held several senior finance roles since 2011, most recently serving as CFO of Teva Canada. Prior to joining Teva, Ms. Brand spent twelve years in finance at Wyeth Pharmaceuticals, a Pfizer company, where she held senior roles including as a Director, Commercial and Corporate Finance. She began her career as an auditor at PriceWaterhouseCoopers (PwC). Ms. Brand is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Science degree in Biology and Business from the University of Toronto.
お知らせ • Aug 02CareRx Corporation to Report Q2, 2024 Results on Aug 08, 2024CareRx Corporation announced that they will report Q2, 2024 results at 7:00 AM, US Eastern Standard Time on Aug 08, 2024
お知らせ • May 30CareRx Corporation Announces Board ChangesCareRx Corporation announced that as part of the Company's commitment to Board refreshment and to realign Board functions to match the Company's strategic focus on operational performance, Kevin Dalton, Chairman of the Board for the last six years, will be retiring as Chairman effectively immediately. Mr. Dalton will be succeeded by Jeff Watson, a current independent director of the Board. Mr. Dalton will be stepping into the role as Chair of the Compensation, Nominating and Governance Committee in place of Maria Perrella, who will continue to remain Chair of the Audit Committee. Mr. Watson has served on the Board of CareRx since 2023 and brings over three decades of experience in the healthcare industry, having most recently served as the President and CEO of Apotex from 2018 to 2023. Mr. Watson currently represents SK Capital Partners on two of their portfolio company boards for Apotex and Woodstock Sterile Solutions, and has previously served on numerous other boards, including as a board member and Chair of the Association for Accessible Medicines (AAM), Chair of the Canadian Generic Pharmaceutical Association (CGPA), and former Chair of the US Healthcare Distribution Alliance's (HDA) knowledge partner, the HDA Research Foundation.
お知らせ • May 15CareRx Corporation Announces CFO TransitionCareRx Corporation announced that Andrew Mok will step down as Chief Financial Officer effective June 7, 2024, to pursue another employment opportunity. The Company is undertaking a search for a new CFO. Davide Pernarella, currently Vice President, Business Planning and Analysis at CareRx, will assume the role of Interim Chief Financial Officer following Mr. Mok's departure. Mr. Pernarella has worked at CareRx for over seven years in various roles with increasing responsibility, and has an intimate knowledge of the financial and business affairs of the Company. Prior to joining CareRx, he held roles in the Transaction Services and Assurance groups at KPMG Canada. Mr. Pernarella is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Commerce degree from the Rotman School of Management at the University of Toronto.
お知らせ • Mar 15CareRx Corporation, Annual General Meeting, May 28, 2024CareRx Corporation, Annual General Meeting, May 28, 2024.
お知らせ • Mar 08CareRx Corporation Reports Goodwill and Intangible Assets Impairment Charges for the Fourth Quarter Ended December 31, 2023CareRx Corporation reported goodwill and intangible assets impairment of $710,000 for the fourth quarter ended December 31, 2023.
お知らせ • Mar 01CareRx Corporation to Report Q4, 2023 Results on Mar 07, 2024CareRx Corporation announced that they will report Q4, 2023 results at 7:00 AM, US Eastern Standard Time on Mar 07, 2024
お知らせ • Nov 02CareRx Corporation to Report Q3, 2023 Results on Nov 08, 2023CareRx Corporation announced that they will report Q3, 2023 results at 7:00 AM, US Eastern Standard Time on Nov 08, 2023
お知らせ • Aug 04CareRx Corporation to Report Q2, 2023 Results on Aug 10, 2023CareRx Corporation announced that they will report Q2, 2023 results at 7:00 AM, US Eastern Standard Time on Aug 10, 2023
お知らせ • Jun 07Carerx Corporation Announces Director ChangesCareRx Corporation appointed Puneet Khanna and Jeff Watson as directors. Company announced that Matt Hills did not stand for re-election.
お知らせ • Jan 19CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million.CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,963,000 Price\Range: CAD 2.7 Discount Per Security: CAD 0.162
お知らせ • May 21CareRx Corporation announced that it has received CAD 63.250644 million in funding from Yorkville Asset Management Inc.On May 19, 2021, CareRx Corporation (TSX:CRRX) closed the transaction. The company issued a total of 12,524,880 subscription receipts for gross proceeds of CAD 63,250,644. The transaction included a portion of non-brokered placement from returning investor Yorkville Asset Management Inc. for 2,277,230 subscription receipts for proceeds of CAD 11,500,011.5 and brokered portion of 10,247,650 subscription receipts for proceeds of CAD 51,750,632.5.